2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2088

Rituximab Use in Pediatric Lupus Anticoagulant Hypoprothrombinemia Syndrome – Report of Three Cases and Review of the Literature

Antiphospholipid Syndrome - Poster II

9:00AM-11:00AM: Abstract Number: 2418

Rnaseq Reveals Treatment-Associated Gene Expression Dynamics in Juvenile Idiopathic Arthritis CD4+ T Cells

Pediatric Rheumatology – Pathogenesis and Genetics - Poster

9:00AM-11:00AM: Abstract Number: 2457

Role of Hydroxychloroquine in Improving Pregnancy Outcomes in Women with Antiphospholipid Antibodies without Other Underlying Connective Tissue Disease

Reproductive Issues in Rheumatic Disorders - Poster

9:00AM-11:00AM: Abstract Number: 2258

Role of NLRP12 on Disease Severity in Autoimmune Arthritis

Innate Immunity and Rheumatic Disease - Poster II

9:00AM-11:00AM: Abstract Number: 2386

Role of Pentraxin 3 in Patients with Juvenile Scleroderma

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

9:00AM-11:00AM: Abstract Number: 2808

Role of Serum Autoantibodies in Blood Brain Barrier Damages in Neuropsychiatric Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2926

Rorc Positive Th17, Th17/Th1, and Th17.1 Cells from the Blood of Treatment NaïVe RA Patients Differ in IL-17A but Are All Pathogenic When Co-Cultured with RA Synovial Fibroblasts

T Cell Biology and Targets in Autoimmune Disease - Poster Session II

9:00AM-11:00AM: Abstract Number: 2152

S100A11 Protein Is Increased in Rheumatoid Arthritis and Is Associated with Disease Activity and Inflammation

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 2896

Safety and Effectiveness of Hyperbaric Oxygen Therapy for Systemic Sclerosis Ulcers

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

9:00AM-11:00AM: Abstract Number: 2625

Safety of Multiple Retreatments with Rituximab in Real Life: Long Term Registry Data from 1984 Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2641

Safety of Synthetic and Biological Dmards: Slr Informing the Update of the EULAR Recommendations for the Management of RA

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2622

Safety, Pharmacokinetics, and Biomarker Profile from Phase 1 Clinical Trials of Healthy Volunteers Treated with GDC-0853, a Highly Selective Reversible Oral Bruton’s Tyrosine Kinase (BTK) Inhibitor

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2717

Sclerostin and Dickkopf-1 but Not Periostin May Have a Role in Psoriatic Arthritis

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster II

9:00AM-11:00AM: Abstract Number: 2757

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 104 Weeks Results from a Phase 3 Trial

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2251

Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis at 52 Weeks from the US Perspective

Health Services Research - Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].